Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients. (1st January 2017)

• Record Type: Journal Article
• Authors: Tian, Jianwei; Hou, Xiaoyan; Hu, Liping; Chen, Ting; Wu, Kefei; Cai, Chudan; Bai, Xiaoyan
• Is Part Of: Renal failure. Volume 39:Number 1(2017)
• Page Start: 153
• Page End: 158
• Publication Date: 2017-01-01
• Subjects: Atorvastatin -- rosuvastatin -- lipid -- microinflammatory -- malnutrition -- hemodialysis; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.1080/0886022X.2016.1256309
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Introduction: To investigate the effect of Atorvastatin (ATO) and Rosuvastatin (ROS) on blood lipid, high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), albumin (ALB), prealbumin (PA), and transferring (TF) in maintenance hemodialysis (MHD) patients. Methods: Eighty MHD patients were enrolled and divided into two groups: ROS and ATO. Patients in Group ROS ( n = 38) received ROS (10 mg/day), and those in group ATO ( n = 42) received ATO (20 mg/day) for 12 weeks, respectively. Findings: Administration of ROS and ATO both significantly reduced the concentrations of TC, LDL-C, TG, hs-CRP, and IL-6, but increased high-density lipoproteincholesterol (HDL-C), ALB, PA, and TF levels. Furthermore, the level of LDL-C decreased more significantly with inhibited microinflammation and improved nutrition situation in ROS group compared with ATO group. ATO and ROS not only decreased blood lipid levels but also inhibited the microinflammatory state and improved nutrition situation in MHD patients. Discussion: The results have shown that ROS is better than ATO in the treatment of MHD patients.